Novavax NVAX Product sales — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novavax's product sales — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Novavax's product sales — total revenue?
- Novavax (NVAX) reported product sales — total revenue of $42.2M in Q1 2026.
- How has Novavax's product sales — total revenue changed year-over-year?
- Novavax's product sales — total revenue decreased by 93.2% year-over-year, from $621.68M to $42.2M.
- What does product sales — total revenue mean?
- This metric represents the total gross revenue recognized from the sale of vaccine products within the specified business segment. It serves as a primary indicator of the company's commercial success and market adoption of its clinical-stage vaccine portfolio.